Transduction of murine and human tumors using recombinant adenovirus vectors

[1]  K. Hunt,et al.  Cytokine-mediated gene therapy for cancer , 1994, Annals of Surgical Oncology.

[2]  M. Walker,et al.  Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. , 1993, Blood.

[3]  M. Perricaudet,et al.  Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. , 1993, Human gene therapy.

[4]  A. McAdam,et al.  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. , 1993, Cancer research.

[5]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Plavec,et al.  Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. , 1993, Cancer research.

[7]  T. Blankenstein,et al.  Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. , 1993, Cancer research.

[8]  E. Gilboa,et al.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. , 1993, Journal of immunology.

[9]  A. Asher,et al.  Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. , 1993, Journal of immunology.

[10]  P. Leder,et al.  Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice , 1993, The Journal of experimental medicine.

[11]  C. Newgard,et al.  Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. , 1992, The Journal of biological chemistry.

[12]  G. Forni,et al.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. , 1992, Journal of immunology.

[13]  C. Tso,et al.  Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. , 1992, Human gene therapy.

[14]  E. Gilboa,et al.  Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. , 1992, Blood.

[15]  E. Gilboa,et al.  Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. , 1992, Cancer research.

[16]  L. Liotta,et al.  Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. , 1992, Cancer research.

[17]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[18]  W. McBride,et al.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.

[19]  M. Zöller,et al.  Reduced tumorigenicity of fibrosarcomas which constitutively generate il‐1α either spontaneously or following il‐1α gene transfer , 1992 .

[20]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[21]  S. Rosenberg,et al.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability , 1992, The Journal of experimental medicine.

[22]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Zöller,et al.  Interleukin‐1 production by transformed fibroblasts. II. Influence on antigen presentation and T‐cell‐mediated anti‐tumor response , 1992, International journal of cancer.

[24]  M. Perricaudet,et al.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.

[25]  T. Blankenstein,et al.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.

[26]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[27]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[28]  H. Volk,et al.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.

[29]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[30]  P. Frost,et al.  Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. , 1991, Cancer research.

[31]  S. Eccles,et al.  Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL‐2 cDNA , 1991, International journal of cancer.

[32]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[33]  T. Blankenstein,et al.  Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. , 1990, Molecular immunology.

[34]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[35]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[36]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[38]  K. Wood,et al.  Firefly luciferase gene: structure and expression in mammalian cells , 1987, Molecular and cellular biology.

[39]  F. Graham,et al.  Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene , 1986, Journal of virology.

[40]  E. Hersh,et al.  Therapy of artificial and spontaneous metastases of murine tumors with maleic anhydride-divinyl ether-2. , 1981, Cancer research.

[41]  M. Suga,et al.  HISTOCHEMICAL STAINS FOR MACROPHAGES IN CELL SMEARS AND TISSUE SECTIONS: β-GALACTOSIDASE, ACID PHOSPHATASE, NONSPECIFIC ESTERASE, SUCCINIC DEHYDROGENASE, AND CYTOCHROME OXIDASE , 1981 .

[42]  L. Milas.  Effects of C. parvum on radiation response of murine tumors. , 1977, Developments in biological standardization.

[43]  L. Peters,et al.  A role for T lymphocytes in the antitumour action of systemic C. parvum. , 1977, Developments in biological standardization.

[44]  L. Peters,et al.  In vivo transfer of antitumor activity by peritoneal exudate cells from mice treated with C. parvum. , 1977, Developments in biological standardization.